Checked
CG Oncology, Inc.
Nasdaq: CGON · Biological Products, (No Diagnostic Substances) · Dallas, TX
- Revenue
- $4.04M
- +254.7% vs. prior year
- Net income
- -$161M
- -3985.0% net margin
- Total assets
- $791.6M
- Diluted EPS
- -$2.08
Company details
As reported to the SEC
- SEC CIK
- 1991792
- Stock
- Nasdaq: CGON
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- Headquarters
- 3000 Pegasus Park Drive, Suite 1640, Dallas, TX 75247
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Large accelerated filer
- Phone
- (949) 409-3700
- Employer ID (EIN)
- 37-1611499
- Last annual report
- 02/27/2026
- Last quarterly report
- 08/06/2026
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 |
|---|---|---|---|
| Revenue | $4.04M | $1.14M | $204K |
| Operating income | -$190.8M | -$114.7M | -$55.45M |
| Net income | -$161M | -$88.04M | -$48.61M |
| Diluted earnings per share | -$2.08 | -$1.41 | -$15.65 |
| Research and development | $116.6M | $82.1M | $45.75M |
| Total assets | $791.6M | $754.8M | $199.3M |
| Total liabilities | $38.99M | $21.42M | $14.51M |
| Shareholders' equity | $752.6M | $733.4M | -$123.1M |
| Cash and cash equivalents | $32.49M | $257.1M | $8.27M |
| Long-term debt | $3M | $0 | Not reported |
| Cash from operations | -$132.3M | -$78.71M | -$45.68M |
| Capital expenditures | $134K | $234K | Not reported |
Federal and state records filed under the name CG Oncology, Inc.
Matched by the company name and by the subsidiary names it lists in SEC filings and other public records, after removing endings like Inc., Corp. and Holdings. Records marked Subsidiary were filed under a subsidiary name. A subsidiary that is not listed in those records is not included, and an unrelated business with the same name can appear.
Work visa sponsorship
Certified H-1B and PERM green card filings with the Department of Labor
| Employer on filing | H-1B | PERM |
|---|---|---|
| CG Oncology, Inc.Irvine, CA | 0 | 1 |
Subsidiaries
3 companies that CG Oncology, Inc. owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| Biovire, Inc. | SEC 10-K |
| SP Healthcare SPV I, LLC | SEC 10-K |
| SafeGuard Healthcare, LLC | SEC 10-K |
Recent filings
74 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
62 insider ownership reports (Forms 3, 4, 5 and 144) were filed about CG Oncology, Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other biological products, (no diagnostic substances)
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Amgen IncAMGN | Thousand Oaks, CA | $36.75B | $7.71B |
| Gilead Sciences, Inc.GILD | Foster City, CA | $29.44B | $8.51B |
| Biogen Inc.BIIB | Cambridge, MA | $9.89B | $1.29B |
| Neurocrine Biosciences IncNBIX | San Diego, CA | $2.86B | $478.6M |
| Exelixis, Inc.EXEL | Alameda, CA | $2.32B | $782.6M |
| Qiagen N.V.QGEN | Pl Venlo, Netherlands | $2.09B | $424.9M |
| Moderna, Inc.MRNA | Cambridge, MA | $1.94B | -$2.82B |
| Halozyme Therapeutics, Inc.HALO | San Diego, CA | $1.4B | $316.9M |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is CG Oncology, Inc.'s CIK number?
- CG Oncology, Inc.'s SEC Central Index Key (CIK) is 1991792.
- What is CG Oncology, Inc.'s stock ticker?
- CG Oncology, Inc. trades as Nasdaq: CGON.
- What was CG Oncology, Inc.'s revenue?
- CG Oncology, Inc. reported revenue of $4.04M for the fiscal year ended Dec 31, 2025, +254.7% from the year before.
- When does CG Oncology, Inc.'s fiscal year end?
- CG Oncology, Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is CG Oncology, Inc. headquartered?
- CG Oncology, Inc.'s principal executive office on file with the SEC is in Dallas, TX.
- What companies does CG Oncology, Inc. own?
- CG Oncology, Inc. lists 3 subsidiaries in its SEC filings and other public records, including Biovire, Inc., SP Healthcare SPV I, LLC, SafeGuard Healthcare, LLC.
- Does CG Oncology, Inc. sponsor H-1B visas?
- Department of Labor records show 0 certified H-1B filings and 1 certified PERM filings under the name CG Oncology, Inc.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026